10-Q: Sonoma Pharmaceuticals Appoints New CFO and Controller, Reports Q3 2024 Results

Sonoma Pharmaceuticals appoints Jerome Dvonch as Chief Financial Officer and John Dal Poggetto as Controller, while also reporting a net loss for the third quarter of fiscal year 2024.

Summary

• Sonoma Pharmaceuticals has appointed Jerome Dvonch as Chief Financial Officer, effective February 7, 2024, and John Dal Poggetto as Controller, also effective February 7, 2024.
• The company reported a net loss of $866,000 for the three months ended December 31, 2023, compared to a net loss of $1,939,000 for the same period in 2022.
• For the nine months ended December 31, 2023, the net loss was $3,768,000, compared to $3,843,000 for the same period in 2022.
• Revenue for the three months ended December 31, 2023, was $3,138,000, an increase from $2,944,000 in the same period of 2022.
• Revenue for the nine months ended December 31, 2023, was $9,296,000, a decrease from $10,258,000 in the same period of 2022.
• The company's cash balance was $2,406,000 as of December 31, 2023, down from $3,820,000 as of March 31, 2023.
• The company has working capital of $9,428,000 as of December 31, 2023, compared to $10,081,000 as of March 31, 2023.
• The company has raised $1,446,000 in net proceeds from a public offering in October 2023 and $356,000 from an at-the-market offering in January 2024.
• The company acknowledges material weaknesses in its internal controls over financial reporting.

Sentiment

Score: 4

Explanation: The document presents mixed results with some positive developments like reduced losses in the quarter and increased revenue, but also significant negatives such as decreased revenue for the nine months, a low cash balance, and material weaknesses in internal controls. The need for additional capital and the going concern warning further dampen the sentiment.

Positives

• The company's net loss decreased significantly for the three months ended December 31, 2023, compared to the same period in 2022.
• The company's revenue increased for the three months ended December 31, 2023, compared to the same period in 2022.
• The company's gross profit margin improved for the three months ended December 31, 2023, compared to the same period in 2022.
• The company successfully raised capital through a public offering and an at-the-market offering.
• The company has expanded its product offerings with new launches in dermatology and wound care.

Negatives

• The company's net loss for the nine months ended December 31, 2023, was still significant at $3,768,000.
• The company's revenue decreased for the nine months ended December 31, 2023, compared to the same period in 2022.
• The company's cash balance decreased from $3,820,000 to $2,406,000 between March 31, 2023 and December 31, 2023.
• The company has identified material weaknesses in its internal controls over financial reporting.
• The company's accumulated deficit has increased to $193,282,000 as of December 31, 2023.

Risks

• The company's ability to continue as a going concern is dependent on securing additional capital.
• The company's reliance on key customers for a significant portion of its revenue poses a risk.
• The company is exposed to risks from fluctuations in foreign currency exchange rates.
• The company faces a substantial Mexico tax liability, intercompany debt, unpaid technical assistance charges and accrued interest.
• The company's failure to maintain compliance with Nasdaq's continued listing requirements could result in the delisting of its common stock.
• The company acknowledges material weaknesses in its internal controls over financial reporting.

Future Outlook

The company expects revenues to fluctuate and may incur losses in the foreseeable future and may need to raise additional capital to pursue product development and market penetration. The company cannot provide any assurances that it will be able to raise additional capital.

Management Comments

• Management believes that the company has access to additional capital resources through possible public or private equity offerings, debt financings, corporate collaborations or other means.
• Management is actively engaged in remediation efforts to address the material weaknesses identified in the managements evaluation of internal controls and procedures.

Industry Context

The company operates in the healthcare sector, specifically in the areas of wound care, dermatology, eye care, animal health, and disinfectants. The company's focus on hypochlorous acid (HOCl) technology positions it in a niche market with potential for growth. The company faces competition from other companies in these sectors, and its ability to penetrate markets and generate attractive margins will be critical to its success.

Comparison to Industry Standards

• Sonoma Pharmaceuticals' revenue growth is mixed, with a 7% increase in the three months ended December 31, 2023, but a 9% decrease for the nine months ended December 31, 2023. This contrasts with some larger pharmaceutical companies that have shown more consistent growth.
• The company's gross profit margin of 47% for the three months ended December 31, 2023, is within the range of some specialty pharmaceutical companies, but lower than some larger, more established players.
• The company's net loss of $3,768,000 for the nine months ended December 31, 2023, is significant and indicates a need for improved profitability. Many comparable companies are either profitable or have a clear path to profitability.
• The company's cash balance of $2,406,000 as of December 31, 2023, is relatively low compared to some of its competitors, highlighting the need for additional capital.
• The company's reliance on key customers for a significant portion of its revenue is a risk factor that is not uncommon in the pharmaceutical industry, but it does make the company more vulnerable to fluctuations in demand from those customers.
• The company's identification of material weaknesses in its internal controls over financial reporting is a concern that needs to be addressed to ensure the accuracy and reliability of its financial statements. This is not uncommon for smaller companies, but it is a critical area for improvement.

Management Changes

Legal Proceedings

• The company may be involved in legal matters arising in the ordinary course of business, including matters involving proprietary technology.

Stakeholder Impact

• Shareholders are impacted by the company's financial performance, the need for additional capital, and the risk of delisting from Nasdaq.
• Employees are impacted by the company's financial stability and the changes in management.
• Customers are impacted by the company's ability to continue to develop and supply its products.
• Suppliers are impacted by the company's financial stability and its ability to pay its obligations.
• Creditors are impacted by the company's financial stability and its ability to repay its debts.

Next Steps

• The company needs to regain compliance with Nasdaq's minimum bid price rule by March 20, 2024.
• The company needs to address the material weaknesses in its internal controls over financial reporting.
• The company needs to secure additional capital to continue its operations and pursue its business plan.
• The company needs to continue to develop and commercialize its products.

Key Dates

Keywords

hypochlorous acid, wound care, dermatology, eye care, animal health, disinfectants, financial results, CFO, controller, internal controls, revenue, net loss, capital raise